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Abstract: Hypoxia is a condition commonly observed in the core of solid tumors. The hypoxia-
inducible factors (HIF) act as hypoxia sensors that orchestrate a coordinated response increasing
the pro-survival and pro-invasive phenotype of cancer cells, and determine a broad metabolic
rewiring. These events favor tumor progression and chemoresistance. The increase in glucose and
amino acid uptake, glycolytic flux, and lactate production; the alterations in glutamine metabolism,
tricarboxylic acid cycle, and oxidative phosphorylation; the high levels of mitochondrial reactive
oxygen species; the modulation of both fatty acid synthesis and oxidation are hallmarks of the
metabolic rewiring induced by hypoxia. This review discusses how metabolic-dependent factors
(e.g., increased acidification of tumor microenvironment coupled with intracellular alkalinization, and
reduced mitochondrial metabolism), and metabolic-independent factors (e.g., increased expression of
drug efflux transporters, stemness maintenance, and epithelial-mesenchymal transition) cooperate
in determining chemoresistance in hypoxia. Specific metabolic modifiers, however, can reverse the
metabolic phenotype of hypoxic tumor areas that are more chemoresistant into the phenotype typical
of chemosensitive cells. We propose these metabolic modifiers, able to reverse the hypoxia-induced
metabolic rewiring, as potential chemosensitizer agents against hypoxic and refractory tumor cells.
Keywords: hypoxia; cancer; metabolic reprogramming; chemoresistance
1. Introduction
Depending on the tissue type, there is a wide variability in the oxygen (O2) levels, ranging from
9.5% (72.0 mmHg) in kidneys [1], 7.6–6.8% (57.6 mmHg-51.6 mmHg) in gastrointestinal tract [2,3],
5.6% (42.8 mmHg) in lungs [4], 5.4% (40.6 mmHg) in liver [5], and 4.4% (33.8 mmHg) in the brain [6].
O2 levels below these values are considered hypoxic. Physiological hypoxia implies an adaptive
and homeostatic response, such as vasodilation and/or up-regulation of hypoxia response genes,
to maintain stable levels of O2. On the contrary, in pathological hypoxia, the homeostatic mechanisms
do not compensate adequately the falling in O2 levels [7].
The fast rate of growth in solid tumors makes them susceptible to O2 shortage in poorly vascularized
areas and leads to the development of intratumoral hypoxic regions [8,9]. Neo-angiogenesis is a
compensative response to intratumoral hypoxia. However, the tumor vasculature is composed of leaky
vessels with chaotic architecture and easy tendency to collapse under the pressure of growing tumor
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and stromal cells [10]. Although the new vessels formed supply O2, the irregular architecture and the
vascular collapse reduce the oxygenation in many tumor areas that reach 1–1.3% (8–10 mmHg) O2
pressure [7,11,12]. The cycling between vessels formation and collapse induces fluctuation of O2 levels,
producing repeated cycles of hypoxia and normoxia within specific areas of tumor bulk [13]. Moreover,
the absence of lymphatic drainage induces intermittent vascular collapse and creates, temporarily
and acutely, hypoxic areas that have been proposed to contribute to progression and/or relapse [14].
Chemotherapy used in cancer treatment can further damage blood vessels, contributing to generate
areas with chronic hypoxia in the tumor mass [11]. Microregions with very low (i.e., near to zero) levels
of O2 are heterogeneously distributed within the tumor bulk, with a prevalence of better oxygenated
areas, characterized by a high rate of cell division and tumor growth around the capillaries. The newly
generated cells often migrate towards the regions far from vessels [15]. Indeed, hypoxia increases
the invasive potential of cells by affecting the extracellular matrix (ECM) [16–18], e.g., by stimulating
the paracrine secretion of soluble factors that generate a fibrotic and stiff ECM, favorable to cell
spreading [19,20]. Notably, even when re-exposed to O2, hypoxic tumors maintain high the expression
of hypoxia-sensitive genes inducing metastasis and resistance to oxidative stress [21], conserving a
“hypoxic memory” that determines a peculiar aggressiveness [22].
Hypoxia not only affects neoplastic cells, but also implies changes in metabolism and functions
of infiltrating cells, such as cancer-associated fibroblasts (CAFs) and tumor-associated macrophages
(TAMs). These changes may impair or favor the neoplastic growth, producing cellular quiescence,
differentiation, apoptosis, or necrosis, depending on the degree, persistence, and severity of hypoxia.
The tolerance to hypoxia, i.e., the ability to enter a quiescent but viable status, determines the persistence
of hypoxia-tolerant cells that are aggressive and hard to be eradicated pharmacologically [23].
As a consequence of the different oxygenation, solid tumors are metabolically heterogeneous:
better oxygenated regions rely on mitochondrial oxidative phosphorylation (OXPHOS), while hypoxic
areas are more dependent on anaerobic metabolism [21]. This metabolic reprogramming is coordinated
by the hypoxia-inducible factors (HIF) family. According to our present knowledge, up to 2% of
the human genome is modulated by HIF transcription factors [24]. This review will focus on the
metabolic rewiring induced by hypoxia, on the implications of such rewiring in tumor progression and
chemoresistance, on the new therapeutic opportunities that may emerge with a deep knowledge of the
metabolic reprogramming occurring in hypoxia.
2. Hypoxia-Inducible Transcription Factors and Hypoxia-Targeted Genes
HIF is a heterodimer formed by two subunits, the O2-regulated HIF-α subunit, and the
O2-independent, constitutively expressed aryl hydrocarbon receptor nuclear translocator (ARNT), also
called HIF-β [24–28]. Three HIF-α homologues have been identified: HIF-1α, HIF-2α, and HIF-3α.
In humans, HIF-1α is expressed in most tissues, HIF-2α is mainly expressed in kidneys, brain, lungs,
liver, gastrointestinal tract, pancreas and heart [29]. HIF-3α is expressed in several tissues [30], but has
a different protein structure [31,32].
The regulation of stability and activity of HIF-1α and HIF-2α is dependent on O2 levels [33].
Indeed, the half-life of the HIF-α subunits in the presence of 21% O2 is less than 5 min, but it
increases to 60 min as the O2 concentration decreases to 1%. Under normoxia, HIF-α subunit
is hydroxylated by prolyl hydroxylase domain (PHD)-containing proteins [33]. This is the result
of the interaction between HIF-α and the von Hippel Lindau tumor suppressor protein (pVHL),
a part of E3-ubiquitin ligase complex, which recognizes two hydroxylated proline residues of HIF-α
(P402 and P564): upon hydroxylation, HIF-α is primed for polyubiquitination and proteasomal
degradation [34,35]. Furthermore, HIF-α subunits are subjected to asparagine hydroxylation at N803
residue: this modification hinders the binding of HIF-1α with the general co-activator p300/CREB
binding protein (CBP)complex [36]. By limiting O2 availability, hypoxia inhibits all of the hydroxylation
processes, restoring its transcriptional efficiency [37,38].
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Moreover, microRNAs (miRNAs) play an important role in HIF-1α stabilization and/or in its
down-stream effects [39]. Indeed, specific miRNAs, termed hypoxia-regulated miRNAs (HRMs),
are differentially expressed in response to hypoxia [40], and modulate angiogenesis, apoptosis,
proliferation, metastasis, and chemoresistance [41].
Besides hypoxia and miRNAs, the stability and activation of HIF-1α and HIF-2α in tumors is also
favored by growth factors, cytokine, and oxidative stress [42]. Several receptor tyrosine kinases (RTKs),
such as epidermal growth factor receptor (EGFR) family members (erbB1 and erbB2/HER2/Neu),
insulin-like growth factor-1 receptor (IGF-1R), stem cell factor (SCF)/KIT receptor, Notch, interleukin-6
receptor (IL-6R) and transforming growth factor-β receptor (TGF-βR) activate HIF-1α. The cooperation
between their downstream transducers, such as phosphatidylinositol 3′-kinase (PI3K)/Akt/molecular
target of rapamycin (mTOR), Ras/mitogen-activated kinase (MEK)/extracellular signal-regulated kinase
(ERK), nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 (STAT3) axes also
increase HIF-1α, by inducing a phosphorylation on serine residues that make the protein less susceptible
to hydroxylation and ubiquitination [9,43]. Additionally, the inactivation of pVHL [37], phosphatase
and tensin homolog deleted on chromosome 10 (PTEN) [44] and p53 [45]—three onco-suppressors
often inactivated or deleted in cancer cells—may block HIF degradation and/or further enhance
PI3K/Akt activation.
The main target genes of HIF-1α are erythropoietin (EPO), the pro-angiogenic vascular endothelial
growth factor (VEGF), the pro-invasive factors metalloproteinase 9 (MMP9) and urokinase-type
plasminogen activator (uPA) [46,47], the glucose-metabolizing enzymes—glucose transporters 1 and 3
(GLUT1 and GLUT3), glycolytic enzymes, such as hexokinase (HK), phosphofructokinase-1 (PFK1),
aldolase, triose-phosphate isomerase (TPI), glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
enolase, lactate dehydrogenase A (LDHA), pyruvate kinase M2 (PKM2), and pyruvate dehydrogenase
kinase 1 (PDK1) [45,48], the amino acids (AA) transporters xCT (SLC7A11), and L-type amino acid
transporter 1 (LAT1/SLC7A5) [49,50], the chemoresistance inducer multidrug resistance 1 (MDR1),
which encodes for the drug efflux transporter P-glycoprotein (Pgp) [51]. Particularly, GLUT1 is an
essential element for glucose uptake in cancer cells and it is a marker of more aggressive tumors [48].
Besides glucose, tumor also needs AA and lipids [52] to meet the increased demand of building blocks
despite the poorly organized intratumoral vasculature [53], and hypoxia affects both these metabolisms.
The majority of the transcriptional programs activated by hypoxia in tumors are due to the activity
of HIF-1α and HIF-2α. The function of HIF-3α remains to be fully elucidated, although it is known to
suppress HIF-1α- and HIF-2α-mediated gene expression and to upregulate a different set of genes [30],
thus, finely tuning the hypoxic response mediated by HIF-1α- and HIF-2α [54].
3. Hypoxia Affects Metabolic Rewiring in Solid Tumors
One of the hallmarks driving aggressiveness in cancer is the reprogramming of energy
metabolism [55]. Glycolysis becomes the predominant energetic pathway, in the presence or absence
of O2, ensuring survival and proliferation [56]. This feature is known as the “Warburg effect” since
Otto Warburg observed for the first time that cancer cells have increased conversion of glucose
to lactate compared to normal cells [57]. In parallel to the enhanced glycolysis, cancer cells are
equipped with several membrane proteins—such as the monocarboxylate transporters (MCTs) and
carbonic anhydrases (CAs)—buffering the end products of anaerobic glycolysis, such as lactate and H+.
These metabolic changes are initiated by oncogenes and perpetuated by the homeostatic alterations
of the tumor microenvironment (TME) [58,59]. Hypoxia is a key factor promoting such metabolic
rewiring, affecting different pathways and compartments (Figure 1).
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Figure 1. Metabolic rewiring induced by hypoxia. (A) In normoxic tumor areas, glucose taken up
by glucose transporter 1 (GLUT1) and transformed by glycolysis into pyruvate is mainly oxidized
into Acetyl-Coenzyme A (AcCoA) by pyruvate dehydrogenase (PDH), fueling the tricarboxylic acid
(TCA) cycle and the electron transport chain to produce ATP. By contrast, lactic fermentation is low.
Fatty acid (FAs) oxidation (FAO) prevails over FA and triglyceride (TG) synthesis, further producing
AcCoA entering the TCA cycle. The oxidative metabolism of glutamine (Gln) is a third anaplerotic
pathway of TCA cycle. (B) Hypoxia enhances glucose uptake via GLUT1 and metabolism into lactate,
thanks to the hypoxia-inducible factor (HIF)-1α-dependent upregulation of glycolytic enzymes, lactate
dehydrogenase (LDH), and pyruvate dehydrogenase kinase 1 that inhibits PDH. In this way, cancer cells
produce huge amounts of lactate, exported by the hypoxia-sensitive gene mono-carboxylate transporter
4 (MCT4) and H+, buffered by other HIF-1α-targeted genes, such as carbonic anhydrase (CA) IX and XII.
Part of lactate can enter the mitochondria via MCT, and is transformed into pyruvate by mitochondrial
LDH, fueling TCA cycle. Notwithstanding such anaplerosis, TCA and electron transport chain (ETC)
are reduced in hypoxic tumors that aberrantly reduce O2 into reactive oxygen species (ROS). Amino
acids (AAs) uptake is increased thanks to the upregulation of xCT and L-type amino acid transporter 1
(LAT1), also induced by HIF-1α. The catabolism of Gln and glutamate (Glu), however, not only fuels
TCA cycle, since it is mainly used to synthesize glutathione (GSH) or produce α-ketoglutarate (αKG)
that is reduced into citrate and NADPH via the reductive glutamine metabolism, providing carbons
for FA and triglycerides (TGs) synthesis. Dotted arrows: down-modulated metabolic pathways; solid
arrows: up-regulated metabolic pathways.
3.1. Glucose Transport and Glycolysis
Cells of solid tumors are often glucose-addicted, although the glycolytic pathway followed by
lactic fermentation has a lower efficiency in terms of glucose/ATP ratio, compared to the glycolysis
followed by tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS). Indeed, although
cancer cells take up glucose at higher rates than normal tissues, they oxidize less glucose in TCA and
OXPHOS, regardless of the presence of O2 [8]. Despite the lower energetic yield, glycolysis is important
in cancer cells because it is a crucial source of intermediates used for the synthesis of macromolecules,
required for proliferation and migration [60]. Indeed, there is a strong linkage between increased
glucose uptake and tumor aggressiveness [61].
Na+-coupled glucose transporters (SGLTs) contribute to glucose uptake in non-transformed
cells, but they are not modified by hypoxia. The main transporters involved in glucose uptake in
cancer cells belong to the GLUTs/SLC2A family [61]. An increased expression of the high affinity
GLUT1 protein has been correlated to metastases and poor prognosis [53,61], appearing a hallmark
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of aggressive tumors. Both hypoxia-dependent and independent mechanisms regulate GLUT1
expression. GLUT1 and GLUT3 are direct target of HIF-1α [56,62], providing a link between hypoxia,
Warburg effects, tumor growth and progression. Moreover, activated Ras and c-Myc, as well as the
pro-tumorigenic antigens E6 and E7 of human papilloma virus (HPV), increase GLUT1 expression [63],
determining a hypoxia-independent increase of glucose uptake and metabolism during the early stages
of tumor progression.
Besides glucose uptake, HIF-1α accelerates the transformation of glucose into lactate, being a
transcriptional inducer of the glycolytic enzymes [9]. In parallel, it prevents the pyruvate mitochondrial
metabolism, by upregulating PDK1, which phosphorylates and inactivates the catalytic subunit of
pyruvate dehydrogenase (PDH) [64]. This event reduces the oxidation of pyruvate to Acetyl Coenzyme
A (AcCoA) and the subsequent entry into the TCA cycle [64]. This is part of an adaptive strategy to the
hypoxic environment, which leads cancer cells to limit the TCA fueling by AcCoA and the subsequent
OXPHOS in the absence of adequate O2 levels.
3.2. Lactate Metabolism and Acidosis
As a result of the increased anaerobic glycolysis, hypoxic areas of tumors produce huge amounts of
lactic acid, which easily dissociates into lactate and H+, promoting the acidosis of TME [65]. Originally
considered as a waste product indicative of stress, lactate has been re-evaluated as an energetic substrate
for cancer cells, as well as a signal molecule promoting tumor progression [65,66]. Lactate is exported
by proteins of MCT family, although their expression is rather variable within tumor bulk and depends
on the different hypoxia degree and cell metabolism. MCT1 transports lactate in well-oxygenated
areas but not in hypoxic regions, whereas MCT4 is the prevalent isoform. In hypoxic areas, MCT4
is co-expressed with HIF-1α [67,68], likely because it is a target gene of HIF-1α [69]. By contrast, the
linkage between MCT1 expression and HIF-1α activity is controversial and tumor-dependent [70,71].
This pattern of distribution of MCTs determines a peculiar metabolic symbiosis within different areas of
tumors, or between cancer cells and non-transformed cells, such as CAFs. Indeed, hypoxic cells, mainly
localized in the tumor core, export lactate via MCT4. Lactate, taken up via MCT1 by more oxygenated
cells—prevalently localized in tumor periphery—is transformed into pyruvate, fueling the oxidative
metabolism of these cells [67,72] or promoting biosynthetic processes [65,73]. Indeed, lactate is imported
within mitochondria via specific MCTs; here, a mitochondrial LDH isoform transforms lactate into
pyruvate, which can act both as an energetic substrate or as a building block [65,73]. The importance
of this metabolic symbiosis between different populations of cancer cells is demonstrated by the
dramatic necrosis occurring in the hypoxic core of solid tumors treated with MCT1 inhibitors [67]
that prevent the lactate shuttle from hypoxic to normoxic areas. A similar symbiosis occurs between
cancer cells and CAFs, because also stromal cells in hypoxic areas activate the same HIF-1α-driven
programs of cancer cells, i.e., they up-regulate GLUT1, glycolytic enzymes, and MCT4 [74]. The lactate
exported by hypoxic CAFs via MCT4 is readily taken up by cancer cells via MCT1 and fuel the
TCA/OXPHOS flux in tumor areas with a sufficient supply of O2, producing the so-called “reverse
Warburg effect” [74,75]. Notably, the increased transformation of lactate into pyruvate also increases
the NADH/NAD+ ratio in cancer cells. This event promotes the sirtuin 1 (SIRT1)-induced deacetylation
and activation of the peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α),
an inducer of mitochondrial biogenesis [76]. As a result, the lactate produced by hypoxic CAFs equips
cancer cells with multiple tools, i.e., energetic substrates, NADH, and mitochondrial mass, which allow
the switch towards an oxidative metabolism if O2 is adequate. Since tumors undergo multiple cycles
of hypoxia and re-oxygenation [13], this switch may help cancer cells to rapidly adapt to the changes
in O2 levels, continuing their growth notwithstanding mutable environmental conditions.
Besides its role as energetic substrate, lactate also promotes tumor progression and invasion.
For instance, it stimulates the synthesis of VEGF by endothelial cells, promoting neo-angiogenesis [65,77].
By increasing the secretion of TGF-β, lactate favors the degradation of extracellular matrix by MMPs,
promoting cancer cell invasion [78] and contributing to tumor progression.
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The co-secretion of H+ with lactate by MCT symporters induces a strong acidification of TME,
which reaches values between 6 and 6.5. Such acidosis determines metabolic reprogramming [79] and
invasiveness [80,81] as well.
Since the glycolytic pacemaker enzyme PFK1 is inhibited by low pH, it is not surprising
that cells growing in acidosis reduce the glycolytic flux, increasing the glucose metabolism in the
pentose phosphate pathway (PPP) [80]. This effect is obtained also by the transcriptional increase
of glucose 6-phosphate dehydrogenase (G6PD), the pacemaker enzyme of PPP [79], and by the
down-regulation of several HIF-1α-target glycolytic genes [82] during acidosis. Similarly, acidosis
up-regulates glutaminase and, consequently, increases glutaminolysis. The oxidation of glutamine
into glutamate and α-ketoglutarate (αKG) fuels the TCA cycle, generating a mitochondrial-dependent
production of ATP [79]. This is relevant to determine cell survival under mild hypoxic conditions.
Indeed, acidosis reshapes mitochondria cristae and maximizes the efficiency of ATP production [83],
even during hypoxia.
An increased fatty acids (FAs) oxidation (FAO) is also observed in acidosis [82]. Such increase has
at least two consequences: on the one hand it fuels the TCA cycle; on the other hand the high levels of
AcCoA promotes an inhibitory acetylation of the complex I of electron transport chain (ETC), reducing
the production of reactive oxygen species (ROS) by OXPHOS [82]. This mechanism, together with
the increased production of NADPH via PPP [80], prevents the oxidative damages of cells growing
in a hypoxic environment. Moreover, the abundance of AcCoA induces the acetylation of SIRT 1/6.
By inducing histone deacetylation, SIRT1/6 downregulate AcCoA carboxylase 2 (ACC2), removing
the negative regulation exerted by malonyl CoA on mitochondrial FAO [82]. SIRT1 also activates
HIF-2, which in turn upregulates enzymes involved in both oxidative and reductive metabolism of
glutamine [84]. The reductive carboxylation of glutamine (see paragraph 3.3. for details) generates
citrate, an excellent source for FA synthesis. Moreover, acidosis increases the transcriptional activity of
the lipogenic factor sterol regulatory element-binding protein 2 (SREBP2), which promotes FA and
cholesterol synthesis, favoring cell proliferation and tumor progression [85]. The co-existence of FAO
and FA synthesis, oxidative and reductive metabolism of glutamine in acidosis, suggests that acidic
cancer cells rely on a metabolic balance, paradoxically based on futile cycles. This situation is likely
consequent to the progressive adaptation to the hypoxic and acidic environment that triggers multiple
metabolic pathways to spare energy and synthesize building blocks. Disrupting such cycles, by using
FAO or glutaminolysis inhibitors [82], may be a promising anticancer strategy against tumor acidosis.
Besides inducing a strong metabolic reprogramming, hypoxia and lactic acidosis favor the
self-maintenance of cancer stem cells (CSCs) [86,87], and activate the pro-metastatic epithelial-
mesenchymal transition (EMT) program. These two events are deeply interconnected: indeed, EMT
increases the migratory and invasive properties of cancer cells, as well as the acquisition of stem cell-like
features [88,89]. An acidic environment stimulates the autocrine production of TGF-β2. First, the
TGF-β2-dependent signaling induces the phosphorylation and acetylation of SMAD family member 2
(Smad2), a driver of EMT [81]. Second, TGF-β2 activates the protein kinase C ζ (PKCζ), which increases
the FA uptake via the scavenger receptor CD36 and the accumulation as triglycerides (TGs) in lipid
droplets [81]. These findings are in keeping with the increased lipogenesis observed in acidosis [83].
Anoikis resistance and invasion are prevented not only by inhibitors of Smad2, but also by inhibitors of
lipogenesis [81]. This observation highlights an unexpected bridge between metabolic reprogramming
induced by acidosis and tumor progression.
Finally, hypoxia and lactic acidosis alter the TME, promoting an immune-suppressive
environment [75]. Hypoxia increases the polarization of TAMs towards a tumor-permissive M2
phenotype and the amount of myeloid-derived suppressive cells (MDSC) infiltrating the tumor [77].
Lactate produced in hypoxic TME has been implicated in the impaired differentiation of monocytes
into dendritic cells (DCs) [90], in the loss of the cytolytic functions by natural killer (NK) cells [91],
in the increases of M2 macrophages [92] and MDSC that inhibit NK activity [93]. Not only lactate
produced by tumor cells, but also lactate originated by the immune-infiltrating cells contributes to
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this immune-suppressive environment. For instance, anti-tumor M1-polarized TAMs are actively
glycolytic in hypoxic areas [93], but MCT4 inhibitors that block the export of lactate from M1 TAMs
induce the polarization towards a M2 phenotype [90]. Active DCs are also highly glycolytic and
export huge amounts of lactate [93]. As observed for TAMs, blocking the export of lactate from
DCs induces the acquisition of an immune-suppressive phenotype, as demonstrated by the lower
ability of recruiting CD8+ T-lymphocytes [90]. Activated T-cells highly rely on anaerobic glycolysis,
as suggested by the upregulation of GLUT1 during T-lymphocyte activation [94]. This process, which is
enhanced by hypoxia, determines the selection of CD8+ T-lymphocytes clones with strong anti-tumor
activities, characterized by high expansion and production of interferon-γ (IFN-γ) [95]. However,
an excessive production of lactate by tumor cells inhibits the export of lactate by MCT1 present on
CD8+ T-lymphocytes: the intracellular acidosis of lymphocytes suppresses the cytotoxic potential and
the production of anti-tumor cytokines [96]. As already described for lactate, the high production of
H+ from cancer cells may affect the efficiency of immune cells in hypoxic areas. For instance, highly
glycolytic tumors producing H+ impair the activation of NK and CD8+ T-lymphocytes because the
low pH inhibits the transcriptional activity of nuclear factor of activated T-cells (NFAT) [97], a master
regulator of T-cells development and activities. Moreover, cancer cells and CD8+ T-lymphocytes
compete for glucose: in hypoxic and highly glycolytic tumors, the scarcity of glucose left to lymphocytes
impair their proliferation and production of IFN-γ [98]. Since the immune-checkpoint PD-1L increases
the glycolysis in cancer cells by activating Akt/mTOR pathway, the use of immune-checkpoint inhibitors
may relieve the competition for glucose between cancer cells and T-lymphocytes [98], restoring the
anti-tumor efficiency of the latter.
Overall the higher export of lactate and the consequent acidosis characterizing hypoxic tumor
areas, the metabolic cross-talks between cancer cells and non-transformed cells within TME (e.g., CAFs
and immune cells) favor proliferation, invasiveness and immune-escape, reducing the efficacy of
anti-tumor pharmacological treatments.
3.3. Amino Acid Transport and Glutaminolysis
As already mentioned, HIF-1α and HIF-2α upregulate the AA transporters xCT (SLC7A11) and
LAT1 (SLC7A5) [49,50]. While the former is a Na+-independent exchanger of cystine and glutamate [99],
the latter is responsible for the transport of large neutral and essential AAs [100]. Both AA transporters
form a heterodimer with the CD98 glycoprotein, which acts as a chaperone promoting stabilization,
trafficking, and insertion of these transporters into the plasma membrane [99].
By importing cystine necessary for the biosynthesis of glutathione (GSH), the main intracellular
anti-oxidant metabolite, xCT plays a key defensive role against oxidative stress and chemotherapy [101].
Although some tissues (e.g., the liver, kidney, and pancreas) can synthesize cysteine from homocysteine
and serine by a transsulfuration pathway [102], in most cells an adequate supply of cysteine is granted
only by the cystine import via xCT. Extracellular cysteine is unstable and quickly oxidized to cystine,
the substrate of xCT: the higher reducing intracellular conditions favor the conversion of cystine into
cysteine and its incorporation into GSH. Notably, the HIF-1α-induced increase in xCT expression and
GSH synthesis favors the survival of the CSC population in triple negative breast cancer (TNBC) [49],
suggesting that during tumor initiation and/or recurrence the HIF-1/xCT/GSH axis has a critical role in
the protection against oxidative stress and in the expansion of stem cell subclones.
Several tumor types also overexpress LAT1 [50,103], which is upregulated by HIF-2α [50].
Concurrently HIF-2α activates mTOR, a sensor of the cellular energy status and of the AA availability,
and a stimulator of protein translation and cell proliferation [104]. mTOR interacts with other proteins
to form two distinct complexes, termed mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2),
the former of which is activated by LAT1 [105]. Hence, HIF-2α/LAT1 axis plays a dual role, by ensuring
the uptake of essential AA within cancer cells, notwithstanding the nutrient-depleted TME, and by
favoring their prompt incorporation into proteins necessary for survival and proliferation.
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Another important reprogramming of cellular energy metabolism in solid tumors is related to the
increased glutaminolysis [106]. Glutamine is an abundant AA, which is involved in energy production
by fueling TCA cycle, in anabolic pathways as source of building blocks for nucleotides, proteins
and plasma membrane glycolipids/glycoproteins, and in oxide-reductive homeostasis, as precursor of
GSH [107]. Besides, glutamine favors lipogenesis by at least two mechanisms. First, αKG metabolized
in the TCA cycle generates malate that is transformed into pyruvate by the malic enzyme: this step
generates reducing equivalents (NADPH), necessary for the synthesis of FAs and sterols [108]. Second,
αKG can be carboxylated to isocitrate by isocitrate dehydrogenase (IDH) [109]. IDH1 is the cytosolic
isoform reversibly transforming αKG into isocitrate and contributing to the reductive metabolism
of glutamine; IDH2 mainly transforms isocitrate into αKG in mitochondria [110], contributing to
the oxidative metabolism of glutamine via TCA cycle. Hypoxia promotes the activity of IDH1,
which generates isocitrate and NADPH, while it reduces the oxidative catabolism of glutamine via
IDH2 [111]. Isocitrate is then transformed into citrate and AcCoA via cytosolic aconitase and citrate
lyase, providing carbon source for lipid synthesis [111]. NADPH supports the reductive steps in FA
and cholesterol synthesis, as well as the maintenance of oxide-reductive balance [112]. The prevalence
of reductive glutamine metabolism in hypoxia has been explained by the inhibition of HIF-1α on
PDH [64,111], which reduces the TCA cycle flux and consequently limits the oxidative metabolism of
glutamine via IDH2. Such shift in glutamine metabolism makes the AcCoA produced by reductive
glutamine carboxylation the most important source for de novo lipogenesis in cells grown under
hypoxia or with high levels of HIF-1α. As proof of concept, pVHL-deficient renal cancer cells
preferentially utilize glutamine metabolism for lipid synthesis even at normal O2 levels [111,113].
Although important, glutamine is not the only AA supporting lipid synthesis in hypoxia. For instance,
the serine catabolism via serine hydroxymethyl transferase 2 (SHMT2) also provides NADPH [114].
Indeed, HIF-2 upregulates SHMT2 that transforms serine into glycine and produces at the same time
methylene-tetrahydrofolate (THF). The oxidation of the latter to 10-formyl-THF by methylene-THF
dehydrogenase produces NADPH [115], which neutralizes ROS and supports lipid synthesis in
hypoxic tumors.
3.4. Fatty Acid Metabolism
Protein and DNA synthesis, commonly accelerated in growing tumors, are energy-consuming
processes [116]. One of the main energy source is represented by endogenous lipids. Moreover, lipids
are also necessary building blocks in the synthesis of plasma membrane and intracellular membranes
of rapidly dividing cells. Interestingly, HIF-1α up-regulates both fatty acid synthase (FASN), the
multimeric complex deputed to FA synthesis, and lipin 1 (LPIN1), a phosphatidate phosphatase
that transforms phosphatidic acid into diacylglycerol, i.e., catalyzing the penultimate step of TG
synthesis [117,118]. This is an important adaptive response of tumors to hypoxia, since it facilitates
FA and TG storage [119], meeting both the energy and synthetic requirements of proliferating cells.
The active endogenous synthesis of lipids also explains the common observation of intracellular lipid
droplets, particularly abundant in hypoxic tumors [120]. The de novo synthesis of FAs supplies
more than 93% of the FAs containing in the TG and phospholipids (PLs) of tumors [121]. The low
consumption of AcCoA within TCA caused by the upregulation of PDK1 and the reductive carboxylation
of glutamine into citrate favored by hypoxia, are additional factors promoting the cytosolic supply of
AcCoA for FASN.
On the other hand, AcCoA can be also generated by FAO. Since cancer cells have increased
lipogenesis in hypoxia, one should expect a reduced lipid catabolism to sustain rapid cell proliferation.
Nevertheless, the scenario is variegate and sometimes contradictory. Indeed, it is a common observation
that the acidosis induced by hypoxia up-regulates both FA synthesis and FAO [82]. In some tumors,
the activation of FAO negatively affects growth and progression [121], in other tumors, FAO is
down-regulated, and its increase reduces cell proliferation [122]. By contrasts, an increased rate of
FAO has been associated with an increased survival of cancer cells in stressful conditions [123,124],
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although the mechanisms remain unclear. Other authors have proposed that FAO is the preferential
source of energy in quiescent cancer cells that have a finely tuned balance between FA synthesis and
FAO, and are less dependent on glucose and glutamine [125]. Moreover, the type of FAs oxidized
impacts on the cell fate. Indeed, cancer growth is suppressed by the expression of long-chain acyl-CoA
dehydrogenase (LCAD), but not by the expression of the medium-chain acyl-CoA dehydrogenase
(MCAD). While both LCAD and MCAD are essential for the first step of FAO in mitochondria, their
substrates and products are different. LCAD preferentially oxidizes long unsaturated FAs; MCAD
preferentially oxidizes saturated FAs. Hence, the suppression of LCAD increases the accumulation of
unsaturated FAs: this is a mechanism inhibiting the PTEN oncosuppressor by upregulating miR-21 in
hepatocellular carcinoma [126], but it has not been reported in other tumor types.
HIF-1α decreases the expression of carnitine palmitoyltransferase 1A (CPT1A), the rate
limiting-enzyme of FAO [127]. CPT1A mRNA levels are lower in slowly-proliferating HER2-positive
and luminal B breast cancer subtypes than in highly proliferating and metastatic TNBC [128], suggesting
that in breast cancer FAO is active more in indolent and slow progressing subtypes. HIF-1α also
down-regulates acyl-CoA dehydrogenases (ACAD), but in this case the reduction of FAO flux is not
paralleled by reduced cell survival and proliferation [129], raising doubts on the biological impact of
such inhibition. Overall, while the role of HIF-1α in rewiring glucose and AA metabolism is clearly
directed to support tumor growth, the impact of hypoxia on lipid metabolism and its biological
meaning is not univocal. The analysis of the differences in tumor types, in enzymatic sets involved in
lipid synthesis and oxidation, in driving oncogenes or oncosuppressor genes, in hypoxia degree may
explain the contrasting evidences and may help to predict if the effects of HIF-1α on lipid anabolic or
catabolic pathways produce cell death or survival.
3.5. Mitochondria in Hypoxic Tumors
Over the last three decades, an attenuated mitochondria metabolism associated to hypoxia has
been reported in several pathological conditions, including cancer [114].
Since hypoxia triggers several mechanisms to adapt tumor cells to low O2 levels and mitochondria
are the major O2 consumers, the physiological consequence of hypoxia is a reduced mitochondrial
OXPHOS. Indeed, in solid tumors hypoxia reduces the activity of the TCA cycle by up-regulating
PDK1 [64,124], inhibits the expression of ETC components [130], represses mitobiogenesis by increasing
the Hes-related family BHLH Transcription Factor With YRPW Motif (HEY) protein [131], alters the
fusion/fission balance [132], increases mitochondrial autophagy by activating the pro-mitophagic factor
BCL2 Interacting Protein 3 (BNIP3) gene [133]. The sum of these events is a quantitative reduction of
mitochondria number and a reduction in their energetic efficiency. On the other hand, the metabolic
symbiosis between hypoxic CAFs or tumor cells and well oxygenated cells [65,73,74], supported by the
lactate shuttle, favors the OXPHOS metabolism in tumor areas, with sufficient levels of O2 or during
re-oxygenation phases. Lactate produced by CAFs increases the mitochondrial mass by upregulating
PGC-1α [76], and mild acidosis associated with hypoxia reshapes mitochondria favoring the optimal
conditions for OXPHOS and ATP synthesis [83]. Consequently, tumor areas characterized by mild
hypoxia or acidosis basically rely on an anaerobic metabolism, but are well equipped to switch towards
a mitochondrial energetic metabolism, adapting to the continuous and mutable changes of O2 levels.
The scarcity of O2 also leads to an incomplete reduction at complex IV of ETC, increasing the
production of partially reduced O2-derived species, i.e., ROS. Mitochondrial ROS (mtROS) can increase
the rate of mutations in mitochondrial DNA (mtDNA) that encodes for 13 subunits of complexes I
to V [134]. The presence of mutated mtDNA, along with the reduced content of mtDNA frequently
observed in tumors with a defective mitobiogenesis [135], are other reasons accounting for the reduced
OXPHOS in hypoxic tumors. This phenotype has been associated with increased invasiveness and
metastases, and with a poor clinical outcome across several cancer types [135]. The presence of
surrounding stroma can partially prevent the loss of mtDNA, as demonstrated by the injection of
mtDNA-deprived tumor cells in mice, which are progressively enriched in mtDNA provided by the
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murine stroma. This process is associated with the recovery of mitochondrial respiratory functions
and to the assembly of new mitochondrial structures [17]. This study suggests that the crosstalk
within different cell populations of the TME may counteract the attenuation of mitochondrial functions
induced by hypoxia. As mentioned before, TME is characterized by repeated cycles of transient hypoxia
followed by re-oxygenation, a condition that—like the ischemia-reperfusion condition—increases
the generation of ROS and the ROS-dependent cell death [64]. Given the harmful role of ROS, the
metabolic reprogramming that limits the level of AcCoA and the TCA cycle flux in hypoxia could
be regarded as an adaptive strategy to limit the production of endogenous and dangerous ROS.
Although the reduction of ROS via the reduction of TCA flux and FAO is considered protective
by some studies [127,136], ROS inactivate the PHD proteins, thereby increasing HIF-1α [137,138].
Experiments of gene knock-down have highlighted that the main sources of mtROS stabilizing HIF-1α
are complex II [139], complex III [140], complex I and TCA cycle enzymes [141]. In addition, specific
oncogenes, such as Ras and c-Myc have been demonstrated to increase O2 uptake and ETC: if these
oncogenes are active in hypoxic tumors, the increased ETC coupled with an uncompleted O2 reduction
increase mtROS [142]. Instead, if ROS are maintained at sub-cytotoxic levels by buffering anti-oxidant
enzymes, ROS contribute to HIF-1α stabilization [42]. Hence, if ROS levels are below the cytotoxic
threshold to induce cell death, they become advantageous molecules for cancer cells, by increasing the
amount of HIF-1α and stimulating the metabolic adaptation to hypoxia, as well as the pro-survival
and pro-invasive programs induced by hypoxia.
4. Hypoxia Induces Chemoresistance by Pleiotropic Mechanisms
Within the same tumor, there are normoxic and hypoxic areas: such heterogeneity determines
metabolic niches that are associated with more chemosensitive or more chemoresistant cells. The latter
are usually characterized by higher stemness and higher tendency to relapse [143]. There are no fixed
division between normoxic and hypoxic areas, but rather a continuum of “metabolically-modulated
niches”, where cells metabolically adapted to survive to changing environmental conditions become
more aggressive and resistant [144]. By activating such adaptive responses, cancer cells are facilitated
not only to survive during O2 oscillations, but also pushed towards progression, resistance to
chemotherapy and radiotherapy [35]. Several factors related or unrelated to the metabolic rewiring
induced by hypoxia are at the basis of chemoresistance.
Among the metabolism-independent factors (Figure 2), one simple reason of the poor efficacy
of chemotherapy is the tumor architecture. Indeed, in solid tumors, the cells in hypoxic regions,
usually far from the vessels, have limited delivery of chemotherapeutic agents because of the
abnormal vascularization [145,146]. Moreover, HIF-1α upregulates multiple genes that contribute
to chemoresistance. One of this is MDR1, encoding for Pgp [51]. Pgp belongs to the adenosine
triphosphate (ATP)-binding cassette (ABC) transporters family and effluxes several chemotherapeutic
drugs unrelated for structure and mechanism of action, contributing to a multidrug resistance (MDR)
phenotype [147]. The HIF-1α-dependent up-regulation of Pgp has been documented in liver [148],
larynx [149], lung [150], and breast [151–153] cancers, as well as in malignant pleural mesothelioma [154]
and B-cells chronic lymphocytic leukemia [155]. The broad range of tumors showing this behavior
suggests that this is a quite conserved mechanism. Moreover, other ABC transporters involved in drug
efflux, such as MDR related protein 1 (MRP1) [156], lung resistance protein (LRP) [157] and breast
cancer resistance protein (BCRP) [158,159], are under the transcriptional control of HIF-1α and HIF-2α,
enlarging the number of drugs that are effluxed and loose efficacy in hypoxic cells.
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Figure 2. Metabolism-independent factors determining chemoresistance in hypoxia. HIF-1α
transcriptionally induces drug efflux transporters belonging to the adenosine triphosphate (ATP)
Binding Cassette (ABC) family, such as ABC transporter B1/multidrug resistance 1 (ABCB1/MDR1,
known as P-glycoprotein/Pgp), ABC transporter G2/breast cancer resistance protein (ABCG2/BCRP),
lung cancer resistance protein (LRP), ABC transporter C1/multi-drugs resistance related protein 1
(ABCC1/MRP1), by cooperating with the transcription factor Nuclear factor erythroid 2-related factor
2 (Nrf2) that also up-regulates anti-oxidant enzymes. Moreover, HIF-1α increases genes that induce
the acquisition of a pro-invasive and stem-like phenotype, such as matrix metalloprotease 9 (MMP9),
C-X-C chemokine receptor type 4 (CXCR4), osteopontin, interleukin-8 (IL-8), and vascular endothelial
growth factor (VEGF), and up-regulates genes promoting DNA repair, such as topoisomerase 2A
(TOP2A), DNA-protein kinases (DNA-PKs), Ku-70, and Ku-80, inhibits TP53 activity, preventing DNA
damage. This complex and coordinated transcriptional program favors cell survival and determines
chemoresistance in cancer cells.
The high number of CSCs in hypoxic tumor areas [86–88] is also associated with chemoresistance,
because CSCs are more refractory to chemotherapy, radiotherapy, and immunotherapy than
differentiated cells [160]. This resistance is partially due to the overexpression of Pgp [161–163] and other
transporters of the same family, such as ABCB5 [164]. In addition, the stabilization of HIF-1α in hypoxic
CSCs may upregulate several genes related to a highly metastatic and poorly chemosensitive phenotype,
such as MMP9, C-X-C chemokine receptor type 4 (CXCR4), osteopontin, IL-8, and VEGF [165,166].
Inhibitors of HIF-1α, such as propofol [167] or tanshinone IIA [168], reversed at the same time EMT
and resistance to docetaxel and doxorubicin, confirming the linkage between hypoxia, EMT, and
chemoresistance. Recently, an additional mechanism—based on a crosstalk between CAFs and cancer
cells—has been described to link chemoresistance and stemness: indeed, the production of TGF-β2,
which typically occurs in an acidic TME [81], from CAFs, increases the intra-tumor expression of GLI2
that favors stemness maintenance in colon cancer and chemoresistance [169]. The endogenous activity
of HIF-1α in CSCs synergizes with the TGF-β2 produced by CAFs in increasing GLI2 production [169],
suggesting that both hypoxia and acidosis cooperate in inducing chemoresistance of CSC component.
At the same time, HIF-1α reduces the efficacy of chemotherapeutic drugs damaging DNA by
upregulating topoisomerase 2A, which reseals DNA double strand breaks [170], by activating DNA
repair machinery enzymes, such as DNA-protein kinases (DNA-PKs), Ku70, and Ku80 [171], and by
downregulating TP53 [172]. The inhibition of TP53 and the consequent resistance to pro-apoptotic
stimuli has also been ascribed to HIF-2α [173].
As already mentioned, ROS are increased in hypoxic tumor areas because of the OXPHOS
dysfunction. The increase in ROS below sub-cytotoxic levels triggers an adaptive response that limits
oxidative damages. One ROS-sensitive factor coordinating this response is the Nuclear factor erythroid
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2-related factor 2 (Nrf2), which upregulates anti-oxidant enzymes and MRP1 [174]. These two events
contribute to chemoresistance, because the overexpression of anti-oxidant enzymes involved in ROS
detoxification [175] also neutralize the ROS produced by chemotherapeutic drugs [176–178]. Moreover,
MRP1 reduces the intracellular retention of chemotherapeutic agents [179].
The metabolic reprogramming induced by hypoxia must also be taken into account as a key player
in inducing cancer chemoresistance.
5. The Metabolic Rewiring Occurring in Hypoxic Tumors Supports Chemoresistance
The metabolic rewiring in both glycolysis and mitochondria induced by hypoxia cause
chemoresistance by cooperating with enhanced pro-survival pathways and reduced apoptosis,
EMT activation, increased DNA repair, alterations in drug metabolism, changes in drug targets [180–182].
The increased acidification of TME produced by the upregulation of glycolytic enzymes and
MCT4 is a first reason of chemoresistance. On the one hand, the low extracellular pH (pHe) favors the
protonation of weak bases, such as anthracyclines, followed by their inactivation and sequestrations
within lysosomes once entered within the cancer cell, a mechanism known as “ion trapping” [183,184].
Second, a typical feature of hypoxic and acidic tumor regions is the increased expression of alkalinizing
enzymes. The Na+/H+ exchanger (NHE) is a typical example of transporter that is up-regulated in
response to the acidification: the increased intracellular pH (pHi) produced by its activity creates the
optimal conditions for Pgp efflux that is maximally efficient at 7.6-7.8 pH [185]. Indeed, restoring pHi
to 7.4–7.2 by blocking NHE reverses the resistance to doxorubicin, a typical Pgp substrate, in colon
cancer cells [186]. Other alkalinizing enzymes are the plasma membrane associated CAIX and CAXII
that are under the direct transcriptional control of HIF-1α [187,188]. CAXII co-localizes with Pgp in
several solid tumors [152] and in particular in the CSC component [188]. Such interaction increases the
catalytic activity of Pgp by creating slightly alkaline pH at plasma membrane level [189].
Chemoresistance in hypoxic tumor areas has also been associated with altered mitochondrial
metabolism, fusion, fission, and mitophagy [190]. On the one hand, since ABC transporters need a
constant supply of ATP, one should expect that hypoxic cells—characterized by lower OXPHOS [131] and
higher mitophagy [191]—provide less ATP to ABC transporters, thus, resulting more chemosensitive.
Contrarily to these expectations, by up-regulating the Bcl-2/adenovirus E1B 19-kDa interacting protein
3 (BNIP3) [192], an inducer of mitophagy, HIF-1α induces chemoresistance to 5-fluorouracil [193],
gemcitabine [176], and cisplatin [177]. Indeed, mitophagy allows an efficient recovery of ATP, reducing
equivalents and building blocks, which support chemoresistance by increasing ABC transporters
activity, prevent the chemotherapy-induced oxidative stress and repair macromolecules damaged
by chemotherapeutic agents. The production of ROS often associated with an altered OXPHOS
in hypoxic tumor regions may induce mtDNA damages that further reduces the efficiency of
OXPHOS [134]. However, such defective mitochondrial energy metabolism triggers a compensatory
response characterized by the upregulation of PGC-1α and PGC-1β, which trigger mitobiogenesis.
This mechanism has been proved to induce resistance to cisplatin in non-small cell lung cancer
with mtDNA mutations that resulted in a 50% reduction of the NADH:ubiquinone oxidoreductase
activity [194]. Overall, the mitochondrial-related parameters (lower OXPHOS and ATP production,
higher ROS, increased mitophagy, increased mtDNA mutations) that characterize the hypoxic tumor
cells induce chemoresistance.
Moreover, cancer cells often have the ability to exploit both glycolysis and OXPHOS, fueled by
glutaminolysis and FAO. In this way, cells shift from one energetic pathway to the other one, according
to the glucose availability [68]. This metabolic plasticity allows meeting the increasing requirements of
energy and building block, necessary to proliferate, migrate, survive, and stimulate neo-angiogenesis
in response to stressing agents as chemotherapeutic drugs [195]. Having a constitutively active
glycolysis [8], but also an increased rate of FAO [127] and glutaminolysis [113], HIF-1α-expressing
cells exhibit a very high metabolic plasticity that allows a better survival in response to glucose
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and O2 shortage, or chemotherapy. We suggest that the pleiotropic effects of hypoxia on metabolic
reprogramming all contribute to chemoresistance by different but cooperating mechanisms.
6. Counteracting Hypoxic Metabolic Rewiring: A New Generation of Chemosensitizing Agents
Over the last two decades, an enormous effort has been done to look for efficient treatments
counteracting chemoresistance. Since the deregulated cell metabolism could cause chemoresistance,
specific metabolic modifiers may be potentially effective as chemosensitizer agents.
The most direct approach consists in targeting HIF-1α, given its central role in controlling
metabolic reprogramming, proliferation, invasion, and chemoresistance. Inhibitors of HIF-1α translation
(EZN-29-68, PX-478, Vorinostat, digoxin), compounds decreasing HIF-1α stability (PX-478, Vorinostat,
YC-1) and transcriptional activity (YC-1, acriflavine), are the most efficient inhibitors of HIF-1α [196–199].
Besides inhibiting directly tumor growth, some inhibitors of HIF-1α transcriptional program, such as
YC-1 [155], BAY87-2243 [200], dutasteride [201], and emetine [202] have shown chemosensitizing
effects in solid and hematologic tumors at preclinical levels. However, the inhibition of physiological
processes controlled by HIF-1α in non-transformed tissues has strongly limited the positive results in
patients (https://clinicaltrials.gov/ct2/results/details?cond=Cancer&term=HIF).
Targeting the metabolic pathways modulated by HIF-1α and involved in chemoresistance could
represent a second chemosensitizing approach (Figure 3).
Cancer cells highly dependent on glycolysis display a dramatic decrease in ATP upon treatment
with the synthetic glucose analog 2-deoxy-D-glucose (2-DG), which blocks the glycolytic flux [203].
Besides exerting strong antitumor effects when used alone, it enhances the effects of chemotherapeutic
agents, such as doxorubicin [204]. Although the same objection raised on HIF-1α inhibitors, i.e., the
low specificity and the toxicity on non-transformed tissues, can be applied to glycolysis inhibitors,
the different dependence from glycolysis between tumor and non-tumor cells make the former more
susceptible to 2-DG cytotoxicity, used at dosages minimally affecting normal cells. In addition,
physiologically produced metabolites, such as melatonin, have revealed an unexpected effect as
anticancer agents, displaying a lower toxicity that synthetic glycolytic inhibitors. Indeed, due to the
ability of downregulating GLUT1 and PDK1, melatonin reduces the glycolytic flux and removes the
inhibition on PDH exerted by PDK1. This rewiring counteracts the energy production dependent on
anaerobic glycolysis [205]. Of note, cancer cells have a lower ability to synthesize melatonin and are
more sensitive to the melatonin’s cytotoxic effects than non-transformed cells [205]: this feature can
be considered a protective mechanism to maintain ATP production. On the other hand, it suggests
that exogenously administered melatonin (that have few side effects on non-transformed cells) can
represent a tumor-selective anti-cancer and chemosensitizing strategy.
A chemosensitizing effect of 2-DG in combination with 5-fluorouracil was reported in vitro and in
hepatocellular carcinoma xenografts [206]. However, escape mechanisms towards metabolic modifiers
have also been reported: indeed, the continuous inhibition of glucose metabolism in tumors treated
with 2-DG selects glycolytic-independent clones that result insensitive to 2-DG and appear more
aggressive, thanks to the activation of compensatory pro-survival pathways [206].
The 3-bromo-pyruvate (3BrPyr) is a potent inhibitor of HK isoform II, one of the pacemaker enzyme
of glycolysis, often overexpressed in tumors; therefore, it induces an ATP crisis. Being an alkylating
agent on HKII and other enzymes, including anti-oxidant enzymes, it has been proposed as a potential
enhancer of alkylating chemotherapeutic drugs. Indeed, 3BrPyr successfully increases the sensitivity
to carmustine in hepatocellular carcinoma cells, by inhibiting glycolysis and inactivating several
targeting proteins involved in redox homeostasis [207]. Both HKII and PDK1, two glycolytic enzymes
upregulated by HIF-1α but inhibited by wild-type TP53, cooperate in inducing chemoresistance to
cisplatin in ovarian cancer, by maintaining high levels of glycolytic flux and pro-survival pathways:
indeed, PDK1 activates Akt signaling that counteracts cisplatin cytotoxic effects [208]. The presence of
mutated TP53 and/or the constitutively activated HIF-1α enhance the chemoresistance; to the contrary,
Cells 2020, 9, 2598 14 of 29
the simultaneous inhibition of HKII and PDK1 restores cisplatin sensitivity by reducing energetic
metabolism and decreasing Akt signaling [208].
Figure 3. Metabolism-dependent factors inducing chemoresistance in hypoxia and possible therapeutic
strategies. In hypoxic tumor areas, HIF-1α increases glucose uptake and anaerobic glycolysis, thanks
to the upregulation of glucose transporter 1 (GLUT1), hexokinase II (HKII), phosphofructokinase
2/phosphofructokinase binding protein 3 (PFK2/PFKBP3), pyruvate kinase M2 (PKM2) and lactate
dehydrogenase A (LDH-A), with consequent export of lactate and H+ via monocarboxylate transporter
4 (MCT4). The decreased extracellular pH inactivates chemotherapeutic drugs, such as anthracyclines,
and is compensated by the Na+/H+ exchanger (NHE) and by the carbonic anhydrase (CA) IX and
XII. These enzymes create a slightly alkaline pH in the plasma membrane, which is optimal for the
catalytic efficiency of ATP binding cassette transporter B1/P-glycoprotein (ABCB1/Pgp). Part of lactate
may enter in the mitochondria via MCT and be transformed into pyruvate by a mitochondrial LDH
isoform. Pyruvate is imported in mitochondria by the mitochondrial pyruvate carrier (MPC), but
the low activity of pyruvate dehydrogenase (PDH) produced by the HIF-1α-driven upregulation of
pyruvate dehydrogenase kinase 1 (PDK1) and the consume of Acetyl Coenzyme A (AcCoA) by fatty
acid (FA) synthase (FASN) reduce the metabolic flow through the tricarboxylic acid (TCA) cycle and
the oxidative phosphorylation (OXPHOS). The reduced mitochondrial metabolism, coupled with
increased mitophagy and compensatory mitogenesis promoted by HIF-1α, results in paradoxically
high levels of ATP, which supports the catalytic activity of ABC transporters, increasing the efflux of
multiple chemotherapeutic drugs. This wide metabolic rewiring induces chemoresistance but it can be
counteracted by metabolic modifiers inhibiting specific enzymes (indicated in red). Abbreviations: 2-DG:
2-deoxy-D-glucose; 3BrPyr: 3-Bromo-pyruvate; EIPA: ethyl-isopropyl amiloride; DCA: dichloroacetate;
mito-CP: mitochondria-targeted carboxy-proxyl nitroxide; TPP+: triphenyl alkyl phosphonium;
mito-DCA: mitochondria-targeted dichloroacetate; mito-metformin: mitochondria-targeted metformin.
PFK binding protein 3 (PFKBP3) is another critical regulator of glycolysis, because it can stimulate or
inhibit PFK-2: recently, the selective PFKBP3 inhibitor PFK158 has shown strong anti-cancer properties,
as well as chemosensitizing effects in ovarian cancers resistant to carboplatin and docetaxel [209].
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PFKBP3 appears a moonlight enzyme: besides regulating glycolysis, it prevents lipid catabolism and
preserve lipid droplets in cancer cells. By inhibiting the ATP production via glycolysis, reducing
lipid droplets and inducing lipophagy [209], PFK158 limits at least two energy sources for tumors,
and reduces the lipid droplet-dependent metastases [81].
Moreover, LDH-A, the last pace-maker glycolytic enzyme and another HIF-1α target gene,
has been correlated with chemoresistance: indeed, it is over-expressed in taxol-resistant TNBC, but its
inhibition with oxamate restores chemosensitivity by inducing apoptosis consequent to the reduced
ATP supply [210]. Notably, chemoresistant cells were more susceptible to the pro-apoptotic effect of
oxamate than the chemosensitive counterpart [210], unveiling a metabolic “Achilles’ heel”.
Since the TME acidification typical of hypoxic areas up-regulates alkalinizing proteins that
contribute to chemoresistance [186,189], targeting these proteins has been also experimented
as chemosensitizing strategy. The NHE inhibitor ethyl-isopropyl amiloride (EIPA) [186], small
molecules [152,187,211] or monoclonal antibodies [212] inhibiting CAXII all successfully reverse
resistance to Pgp substrates, such as anthracycline and temozolomide. Another approach to reduce
acidosis is blocking the H+/lactate symporters. MCT1 inhibitors, such as α-cyano-4-hydroxycinnamate
(CHC), AR-C155858 and AZD3965, have been shown to reduce tumor growth and progression [67,213],
with limited toxicity in vivo. The main limitation of MCT1 inhibitors, however, is the low specificity.
For instance, AR-C155858 has a strong suppressive activity against CD8+ T-lymphocytes, which need
an active MCT1 to preserve their cytotoxic functions [96]. Moreover, blocking MCT1 force cell to
increase the rate of glucose oxidation via the TCA cycle and OXPHOS, cancelling the desired anticancer
effect of MCT1 inhibitors. For this reason, inhibitors of the mitochondrial pyruvate carrier (MPC)
such as 7ACC2, which prevents the entry of pyruvate into TCA/OXPHOS flux, result more effective
in reducing tumor growth [214]. Besides producing an ATP crash, the inhibition of MPC has the
advantage of reducing the O2 consumption by mitochondria, relieving the intratumoral hypoxia,
allowing radiosensitization [214] and likely chemosensitization. Finally, it must be considered that
the presence of both MCT1 and MCT4 within different tumor areas may limit the efficacy of MCT
inhibitors. Indeed, the block of one isoform often induces the compensatory up-regulation of the
other isoform [213], preserving the efflux of lactate and the acidification of TME. The simultaneous
use of inhibitors of MCT1 and MCT4, such as AZ93, may increase the efficacy of this approach [213],
by promoting the shift of cancer cells from a glycolytic-based metabolism toward a OXPHOS-based
metabolism. At the moment, however, the presence of severe side toxicity of MPC or MCT inhibitors
are the major limitations of their use.
Notwithstanding possible toxicities, the shift from a glycolytic to an OXPHOS-based metabolism
strongly kill hypoxic cancer cells that rely on glycolysis for their energy production. The glycolysis to
OXPHOS shift is achieved for instance by the PDK1 inhibitor dichloroacetate (DCA) that relieves the
inhibition on PDH, allowing the generation of AcCoA and fueling TCA cycle [215]. In these conditions,
the defective OXPHOS of hypoxic tumors, not trained to have an efficient ETC, may increase the
rate of mistakes, e.g., the amount of uncompleted reduction of O2. In turns, the increase in ROS
may induce cell death and synergize with chemotherapeutic agents producing ROS, such as cisplatin.
On the other hand, the increased amount of ATP derived from OXPHOS, although not sufficient to
protect from apoptosis, reduces the glycolytic flux with a feedback inhibition on PFK-2, completely
counteracting the metabolic reprogramming induced by hypoxia. Moreover, a direct inhibition of DCA
on HIF-1α activity has been documented: this inhibition further contributes to chemosensitization
via the direct downregulation of Pgp [215]. The supplementation of doxorubicin-resistant colon
cancer and malignant pleural mesothelioma cells, constitutively expressing HIF-1α, with pyruvate
restores the sensitivity to doxorubicin: the mechanisms is similar to that of DCA, because pyruvate
increases ETC and suppresses glycolysis [216], reversing the metabolic phenotype supported by HIF-1α.
The increased OXPHOS and the consequent increase of mtROS may explain the chemosensitization
to doxorubicin.
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Dual targeting compounds, i.e., agents reprogramming at least two metabolic pathways as DCA
and pyruvate, are the most effective chemosensitizing strategies among the metabolic modifiers.
In etoposide-resistant neuroblastoma, a constitutively high level of anti-apoptotic survivins induce
mitochondria fission, downregulate OXPHOS and increase glycolysis: this signature, similar to that
produced by HIF-1α, is associated to a metastatic and chemoresistant phenotype. By relying mainly on
glycolysis to obtain ATP, resistant neuroblastoma cells are highly susceptible to glycolytic inhibitors:
indeed, the treatment with 2-DG reprograms the metabolic phenotype of resistant neuroblastoma and at
the same time sensitizes cells to etoposide [217]. The combination of two different metabolic modifiers
also achieve a wide reprogramming: for instance, the mitochondria-targeted carboxy-proxyl nitroxide
(mito-CP) compound inhibits mitochondrial metabolism, increases the levels of citrate that cannot be
metabolized in the TCA cycle, but it is exported in the cytosol, and inhibits glycolysis at the PFK-2 step.
In association with 2-DG, mito-CP strongly induces apoptosis in pancreatic adenocarcinoma [218],
one of the most chemoresistant tumor, demonstrating that the combined use of metabolic modifiers
may be effective against refractory cancers. Similarly, the simultaneous inhibition of glycolysis with
2-DG or lonidamine, and of FAO with etomoxir, enhances the anti-cancer effect of arsenic trioxide
(AsO) in acute pro-myelocytic leukemia cells [219]: the mechanism is related to a significant drop
in ATP levels and to a down-regulation of the pro-survival ERK1/2 and Akt-dependent pathways.
Although no toxic effects were reported on peripheral blood monocytes in vitro [219], a severe toxicity
of combination therapies cannot be excluded in vivo, considering that glycolysis and FAO, i.e., the two
main energy pathways for most tissues, are blocked. Similarly, combination therapies based on MCT
inhibitors and OXPHOS inhibitors [213], may represent an effectively lethal tool against chemoresistant
cells in hypoxic tumor regions. Also in this case, the potential toxicity represents the main limitation,
since these combinatorial approaches induce a metabolic catastrophe.
Since hypoxia increases FA synthesis, agents targeting this pathway may contribute to
chemosensitization. For instance, the FASN inhibitor Orlistat induces chemosensitization to cisplatin
in T-cell lymphoma, by pleiotropic mechanisms, including increased ROS levels, decreased MCT1
expression and lactate efflux, downregulated Pgp and MRP1 [220]. Although the linkages connecting
all these events and the levels of HIF-1α have not been evaluated in this study, it may pave the way to
consider the targeting of FA metabolism as a new chemosensitizing approach.
Several small molecules altering mitochondria metabolism, termed “mitocans”, have shown
promising anti-cancer efficacy [221], in particular in tumors where glycolysis has a minor role in producing
ATP. Since mitochondrial metabolism is often attenuated in hypoxic tumors, it could be further deranged by
mitocans, to produce a deep energetic crash, induce apoptosis and chemosensitization [222]. The potential
across the inner membrane of mitochondria is highly negative inside (~ −180 mV). This difference
allows lipophilic cations, such as triphenyl alkyl phosphonium (TPP+) to accumulate preferentially
within mitochondria [221]. Phenol TPP+-derivatives have recently shown to lower mitochondrial
biogenesis, mitochondrial mass and energetic metabolism, increasing at the same time the mtROS
levels, opening the membrane permeability transition pore, and triggering a caspase-9-mediated
apoptosis [223]. By reducing OXPHOS and increasing mtROS, TPP+-derivatives may worsen the
energetic mitochondrial metabolism of hypoxic cancer cells and increase at the same time the
possible oxidative damages. They could be exploited as chemosensitizers in hypoxic areas of tumors,
in combination with chemotherapeutic drugs that generate ROS, such as cisplatin, gemcitabine,
or doxorubicin [176–179]. The TPP+-conjugate of DCA (mito-DCA) is a synthetic derivative of DCA,
conceived as a more potent version of parental compound: the vectorization to mitochondria amplifies
the inhibition of PDK1 and the consequent shift from glycolysis to OXPHOS [224]. This property
can be exploited in hypoxic cells that heavily rely on glycolysis for their energy requirements.
The anti-diabetic drug metformin has been repurposed as a potential anti-cancer drug, as it inhibits
complex I of ETC [225]. Various mitochondria-targeted metformin analogues, with different alkyl
chain lengths, have been synthesized, with the aim of strengthening the inhibition of OXPHOS.
The anti-proliferative effects of mito-metformin increase with the increasing length of alkyl chain [226].
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As a consequence of the strong inhibition of OXPHOS, these mito-metformin increase the production
of •O2− and H2O2, and are radio-sensitizers in pancreatic cancer cells [226]. Thanks to their ability
of increasing mtROS, they could be potential chemosensitizer agents. Similarly, the increase of
mtROS in chemoresistant cells constitutively expressing HIF-1α has been achieved by the metronomic
administration of doxorubicin: two consecutive low doses of the drug increases the ETC flux but also the
mtROS that damage the mitochondrial membrane, decrease the yield of ATP and trigger apoptosis [227],
fully restoring chemosensitivity. The increase in mtROS is not the only mechanism explaining the
anti-cancer efficacy of OXPHOS inhibitors. For instance, the complex I inhibitor IACS-010759 shows
good anti-cancer activity because of the marked reduction in energy production and in aspartate
regeneration via TCA-dependent cataplerotic/anaplerotic pathways. The low ATP synthesis and the
reduced pyrimidine synthesis caused by the lower aspartate levels explain the anti-cancer efficacy of
IACS-010759, currently approved in phase I trials for acute myeloid leukemia and glioblastoma [228].
IACS-010759 has overcome the common limitations observed by other OXPHOS targeting agents,
such as off-target effects and unfavorable pharmacokinetic profile [228], showing acceptable toxicity in
non-transformed cells if used in the proper therapeutic window. Notably, IACS-010759 belongs to a
library of compounds with high specificity for complex I and for cells relying on OXPHOS to produce
ATP [228]. For this reason, the compound, which does not affect HIF-1α transcriptional program,
is effective in glucose-deprived hypoxic cells [229]. Moreover, it can be considered a good metabolic
modifier in acidosis that downregulates HIF-1α transcriptional program and glycolytic enzymes [83],
forcing cancer cells to rely mainly on OXPHOS to meet their demand of ATP.
Overall, these pharmacological evidences demonstrate that shifting the glycolysis/OXPHOS
balance may be an effective chemosensitizing strategy against hypoxic tumor cells.
7. Conclusions and Future Perspectives
This review provides a deep analysis of the linkages between hypoxia, metabolic rewiring, and
chemoresistance in cancers. Drug resistance is well known as the primary cause of therapeutic failure
in cancer treatment. The mechanisms of chemoresistance involve a combination of cell-intrinsic factors
such as oncogenic drivers or mutations, TME-associated factors, pharmacokinetic factors. Hypoxia
is a common feature of TME. It plays an important role in selecting cells challenged by a low O2
supply and forced to rewire their metabolism. This training to survive under unfavorable conditions
inevitably make cells more resistant to exogenous stresses such as chemotherapy. HIF-1α-dependent
chemoresistance relies on the transcriptional activation of genes determining cell proliferation,
metastasis, EMT, maintenance of stem cell-like properties, drug efflux, and metabolic reprogramming.
The typical metabolic signature of hypoxic tumors is characterized by increased glucose uptake and
fermentation into lactate, decreased pHe/increased pHi, reduced TCA cycle and OXPHOS, increased
production of mtROS, increased uptake of AAs, and increased synthesis of anti-oxidant metabolites
as GSH. All of these features contribute to chemoresistance. The accelerated glycolysis supplies
cells with sufficient ATP to promote cell survival and with glycolysis intermediates for biosynthetic
purposes. The increased mitophagy characterizing hypoxic cells sustains the possibility of recovering
ATP. The altered pH inactivates several drugs that are active as weak bases, or sequesters them into
lysosomes after protonation. The increased production of sub-cytotoxic mtROS, coupled with the
higher levels of anti-oxidant metabolites, train cells to be less susceptible to the oxidative damage
induced by chemotherapy.
If targeting HIF-1α could represent an effective approach because it blocks a great number of
processes determining chemoresistance, HIF-1α inhibitors have the disadvantage of huge toxicity, due to
the inhibition of physiologically important HIF-1α-dependent processes, such as ischemia-reperfusion
response in non-transformed tissues. Targeting the metabolic pathways controlled by HIF-1α and
re-programming them as in normoxic cells may improve the efficacy of chemotherapeutic drugs and/or
attenuate chemoresistance. Although metabolic modifiers have already been tested in clinical trials,
side effects deriving from the inhibition of metabolic pathways in non-transformed tissues cannot
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be excluded. However, the metabolic signature of hypoxic cancer cells—based on high anaerobic
glycolysis and low mitochondrial metabolism—is quantitatively different from the normal tissues.
This quantitative difference may open a therapeutic window at which metabolic modifiers could be safely
used against hypoxic cancer cells, without damaging non-transformed tissues. Nanotechnology-based
drug delivery, employing tumor-targeting liposomes or nanoparticles, could aid to increase the
delivery and the vectorization of the metabolic modifiers towards the tumor, increasing the therapeutic
benefits and reducing the side effects. Finally, some endogenous metabolites, such as pyruvate or
melatonin, differentially produced by hypoxic cells and non-tumor tissues, have revealed significant
chemosensitizing properties, coupled with lower risks of toxicity.
Thanks to the deep knowledge of the metabolic rewiring induced by hypoxia, and causing
chemoresistance, a precision medicine based on specific metabolic modifiers can be proposed as a
novel chemosensitizing strategy against aggressive and refractory tumors.
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